Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection44
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective30
The making of the one pill—Developing single tablet regimens for HIV and for HCV23
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting20
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts16
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation16
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants16
Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam14
Commentary: John C. Martin (1951–2021)13
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study13
A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir12
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity12
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway11
Tenofovir alafenamide fumarate11
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir10
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines9
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud9
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report9
A favipiravir-induced angioedema and urticaria in a COVID-19 patient8
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review7
Pharmacokinetic and mass balance characterization of [ 14 C] RAY1216, a SARS-CoV-2 M pro inhibitor, in healthy Chinese male subjec7
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study7
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach6
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database6
The transformation of HIV therapy: One pill once a day6
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis6
0.15033507347107